Core Insights - Tevogen Bio has entered into an agreement with CD8 Technology Services LLC to develop a turn-key facility for in-house pre-clinical research and GMP cell therapy production capabilities [2][3] - The agreement is part of Tevogen Bio's long-term strategy to enhance development timelines, maintain operational flexibility, and control costs [3] - This milestone is seen as a significant step in expanding Tevogen Bio's infrastructure to support its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics [4] Agreement Details - The agreement has an initial term of 12 months and will automatically renew, aligning with previously announced topline forecasts [3] - Tevogen Bio will provide the primary staff and operations for the facility, which is expected to help overcome capital barriers typically faced in building GMP capabilities at scale [3][4] - Specific details regarding the facility, including scope of work, costs, and timelines, will be outlined in future work orders [4] Leadership Commentary - Ryan Saadi, CEO of Tevogen Bio, emphasized the importance of this agreement in advancing the company's mission to help patients and in recognizing long-term shareholders [4]
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility